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Evidence has accumulated for the involvement of Ca2þ in the pathophysiology of mood disorders.
Elevations in both resting and stimulated intracellular Ca2þ levels in patients with affective disorders
have been reported. The role of inositol-1,4,5-trisphosphate receptors (InsP3Rs), which allow mobiliza-
tion of intracellular Ca2þ stores, was, then, investigated in the mouse forced swimming test. InsP3R
antagonists (heparin, xestospongin C) as well as an inositol monophosphatase inhibitor (LiCl) showed an
antidepressant activity of intensity comparable to clinically used antidepressants. InsP3Rl, InsP3R2 and
InsP3R3 knockdown mice were obtained to investigate the role of InsP3R isoforms. We generated mice
carrying a cerebral knockdown of InsP3Rl, InsP3R2 and InsP3R3 proteins by administering antisense
oligonucleotides complementary to the sequence of InsP3Rl, InsP3R2 and InsP3R3. These antisense-
treated mice showed a specific InsP3R protein level reduction in the mouse cerebral cortex and
hippocampus, demonstrated by immunoblotting, immunoprecipitation and immunocytochemistry
experiments. Knockdown mice for each InsP3R isoforms showed an antidepressant behaviour and the
induced phenotype was reversible disappearing 7 days after the end of the treatment. The absence of
impairment of locomotor activity and spontaneous mobility in InsP3R knockdown mice was revealed.
These results indicate the involvement of the InsP3R-mediated pathway in the modulation of depressive
conditions and may be useful for the development of new therapeutical strategies for the treatment of
mood disorders.
 2008 Elsevier Ltd. All rights reserved.2þ1. Introduction
Calcium is a ubiquitous intracellular signalling molecule that is
required for initiating and regulating a wide range of neuronal
functions, including neurotransmitter release, synaptic plasticity,
neurite outgrowth, and neurodegeneration (Berridge, 1998;
Ciccolini et al., 2003). The regulation of free intracellular Ca2þ is
a complex, multifaceted process regulated by various mechanisms
related to physiological functions. One mechanism is the influx
of Ca2þ via Ca2þ channels through the plasma membrane. Another
is the release of Ca2þ from intracellular stores via intracellular
Ca2þ-release channels, the inositol 1,4,5-trisphosphate receptor
(InsP3R) and the ryanodine receptor (RyR): InsP3R is a keyi.c.v., intracerebroventricular;
nsP3R2, type 2 inositol-1,4,5-
,5-trisphosphate receptor; D-
asodium salt; L-myo-inositol,
t; s.c., subcutaneous.
logy, University of Florence,
055 4271313; fax: þ39 055
otti).
All rights reserved.molecule for InsP3-induced Ca release, whereas RyR is impor-
tant for Ca2þ-induced Ca2þ release (Foskett et al., 2007; Zalk et al.,
2007). Considering the importance of calcium signals for cellular
functions, it is not surprising that functional abnormalities in
endoplasmic calcium channels are also involved in pathological
conditions that are related to disturbance in calcium homeostasis.
Several skeletal-muscle pathologies such as malignant hyper-
thermia, porcine stress syndrome, central-core disease, can be
caused by mutations in ryanodine receptors (Missiaen et al.,
2000). Brain InsP3Rs have been hypothesized to contribute to the
pathology of episthotonos in mice (Street et al., 1997). Disturbance
in InsP3R and RyR appears to be involved in neurodegenerative
diseases such as Alzheimer’s disease (Mattson and Chan, 2003).
Evidence has accumulated for the involvement of Ca2þ also in
the pathophysiology of mood disorders. Platelet intracellular
calcium mobilization stimulated by serotonin is enhanced in
depressed patients (bipolar, major, melancholic) in comparison
with normal subjects (Kusumi et al., 1991; Mikuni et al., 1992;
Eckert et al., 1993; Tomiyoshi et al., 1999). In platelets from
unmedicated bipolar patients, the increase in intracellular
calcium after thrombin stimulation is significantly higher than
that measured in healthy controls (Kusumi et al., 1992; Suzuki
et al., 2001). Some investigations also suggested that baseline
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blasts of patients with bipolar affective disorders (Dubovsky et al.,
1994; Emamghoreishi et al., 1997). Understanding the basis for this
dysregulation of calcium homeostasis will be crucial for under-
standing the pathogenesis of affective disorders.
Even if elevations in both resting and stimulated intracellular
Ca2þ levels in patients with affective disorders have been reported,
little is known on the involvement of the intracellular Ca2þ-release
channels in mood disorders. Three distinct receptors recognise
InsP3, named InsP3Rl, InsP3R2 and insP3R3. InsP3Rs are recognized
as a protein family of tetrameric ligand-gated Ca2þ channels, which
allow mobilization of intracellular Ca2þ stores in response to acti-
vation of cell surface receptors linked to InsP3 generation (Berridge,
1993). InsP3R monomers are large proteins with a calculated
molecular mass of about 300 kDa and all three isoforms of InsP3R
share 60–70% amino acid similarity (Taylor et al., 1999). The aim of
this study was to determine the role of the three InsP3R isoforms in
a depressive task by using the mouse forced swimming test. To this
purposewe inhibited the expression of each InsP3 receptor subtype
by using antisense oligonucleotides targeting InsP3R mRNA
sequences, which are unique in the mouse genome, and therefore
assure stringent target selectivity.
2. Experimental procedures
2.1. Antisense oligonucleotides
Phosphodiester oligonucleotides (ODNs) protected by terminal phosphor-
othioate double substitution (capped ODNs) against exonuclease-mediated degra-
dation were purchased from Tib-Molbiol (Genoa, Italy). The sequences are the
following: anti-IP3Rl: 50-C*T*C GAC ATT TTG TCA GAC* A*T-30 , targeting the mRNA
(Genbank NM_010585.2) at positions 329–348; anti-IP3R2: 50-A*G*G AAG CTG GAC
ATT TTG* T*C-30 targeting the mRNA (Genbank NM_019923.3) at positions 41–60;
anti-IP3R3: 50-C*T*G GAC ATT TCA TTC ATG* G*C-30 targeting the mRNA (Genbank
NM_080553.2) at positions 48–67 (* indicates phosphorothioate residues). A 20-
mer fully degenerated ODN (dODN) 50-N*N*N NNN NNN NNN NNN NNN* N*N-30
(where N is G, or C, or A, or T) was used as a control ODN. ODNs were vehiculated
intracellularly by an artificial cationic lipid (DOTAP, Sigma, Italy) to enhance both
uptake and stability. aODNs or dODNs were preincubated at 37 C for 30 min with
13 mMDOTAP and supplied to mice by i.c.v. injection of 5 ml solution on days 1, 2 and
3. Behavioural tests were performed on day 4, 24 h after the last i.c.v. injection of
ODNs.
2.2. Preparation of membranes
Mouse brains were dissected to separate specific areas. Mouse cerebellum,
hippocampus, cortex and striatumwere homogenized in an homogenization buffer.
The homogenate was centrifuged at 9000  g for 15 min at 4 C and the low speed
pellet was discarded. The microsomal membranes were obtained from the super-
natant of the 9000  g spin by centrifugation at 100,000  g for 1 h at 4 C.
Microsomes were resuspended in homogenization buffer and stored at 80 C.
Protein concentration of the microsomal fraction was quantified using a protein
assay kit (Bio RadLaboratories, Milan, Italy).
2.3. Immunoblot analysis
Membrane homogenates (30 mg) of control and antisense-treated mice were
separated on 6% SDS-PAGE and transferred onto nitrocellulose membranes (60 min
at 100 V) using standard procedures. Membrane was blocked in PBST (PBS con-
taining 0.1% Tween) containing 5% non-fat dry milk for 90 min. Following washings,
blots were incubated overnight at 4 C with specific antibodies (SantaCruz
Biotechnology, CA, USA) against InsP3Rl, InsP3R2 or InsP3R3 (1:1000 dilution). After
being washed with PBST, the nitrocellulose membrane was incubated with rabbit
anti-goat horseradish peroxidase-conjugated secondary antisera (1:10,000) and left
for 1 h at room temperature. Blots were then extensively washed according to the
manufacturer’s instruction and developed using enhanced chemiluminescence
detection system (Pierce, Milan, Italy). Exposition and developing time used were
standardized for all the blots. Densitometric analysis of scanned images was per-
formed on aMacintosh iMac computer using the public domain NIH Image program.
Measurements in control samples were assigned a relative value of 100%.
2.4. Immunoprecipitation of InsP3Rl, InsP3R2 and InsP3R3
Immunoprecipitationwas carried out on 1 ml of microsomal fraction containing
100 mg proteins by incubation for 2 h at 4 C with 10 mg of specific antibodies againstInsP3Rl, InsP3R2 or InsP3R3. All tubes then received 20 ml of 25% (v/v) Protein
G-Agarose (Santa Cruz Biotechnology, CA, USA) and incubated for further 2 h at 4 C.
Pellets were collected by centrifugation at 1000  g for 5 min at 4 C, washed three
times with homogenization buffer. Pellets were finally resuspended in 40 ml elec-
trophoresis sample buffer, boiled for 5 min, and samples were processed by SDS-
PAGE.
2.5. Tissue processing and immunocytochemistry InsP3Rs
Mice were anesthetized with chloral hydrate 12% and perfused with para-
formaldehyde 4% in 0.1 M phosphate buffer. The brains were removed and post-
fixed in the same fixative for 4 h at 4 C. Afterpost-fixation tissues were transferred
to 0.1 M phosphate buffer containing sucrose 18%, and then frozen in isopentane
at 5 C. Floating sections (40 mm thick) were cut with cryostat LEICA CM1800. For
antigen retrieval the slides were incubated in 10 mM sodium citrate (pH ¼ 6) at
80 C for 30 min. Sections were rinsed with 0.1% Triton in PBS and incubated in
blocking solution for 30 min at room temperature. Blocking solution contained 2%
non-fat dry milk and 0.1% Triton in PBS. Sections were then incubated 48 h at 4 C
with a primary polyclonal anti-InsP3Rl, anti-InsP3R2 or anti-InsP3R3 (1:100) (Santa
Cruz Biotechnology Inc., Santa Cruz, CA), or anti-RyR2 (kind gift of Prof. Sorrentino,
University of Siena, Italy). After rinsing in 0.1% Triton PBS, sections were incubated
for 1 h at RT with diluted biotinylated secondary antibody solution (1:200). The6
sections were stained using the avidin–biotin–peroxidase complex (ABC) method
with a Vectastain Kit (Vector Laboratories Inc., Burlingame, CA) and then washed in
PBS before development with DAB method (Vector Laboratories Inc., Burlingame,
CA). Sections were rinsed with PBS and mounted on gelatinized glass slides. After
dehydration in graded alcohol solutions, the sections were coverslipped with Pertex
(Histo-line Laboratories, Milano, Italy).
2.6. Animals
Male Swiss albino mice (23–25 g) were used. Fifteen mice were housed per cage
(26  41 cm). The cages were placed in the experimental room 24 h before the test
for acclimatization. The animals were fed a standard laboratory diet and tapwater ad
libitum and kept at 23 þ 1 C with a 12 h light/dark cycle, light on at 7 a.m. Animals
were naive and used only once. All experiments were carried out in accordance with
the Guide for the Care and Use of Laboratory Animals as adopted and promulgated
by the National Institutes of Health.
2.7. Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was performed under ether
anesthesia, as previously described (Galeotti et al., 2003). During anaesthesia, mice
were grasped firmly by the loose skin behind the head. A hypodermic needle
(0.4 mm external diameter) attached to a 10 ml syringe was inserted perpendicularly
through the skull and no more than 2 mm into the brain of the mouse, where 5 ml
solution were then administered. The injection site was 1 mm to the right or left
from the midpoint on a line drawn through to the anterior base of the ears. Injec-
tions were performed randomly into the right or left ventricle. To ascertain that
solutions were administered exactly into the cerebral ventricle, some mice were
injected with 5 ml of diluted 1:10 India ink and their brains were examined
macroscopically after sectioning. The accuracy of the injection technique was
evaluated with 95% of injections being correct.
Drug concentrations were prepared so that the necessary dose could be
administered in a volume of 5 ml per mouse.
2.8. Forced swimming test
The forced swimming test used was the same as described by Porsolt et al.
(1977). Briefly, mice were dropped individually into glass cylinders (height: 25 cm,
diameter: 10 cm) containing 6 cm of water maintained at 22–23 C and left there for
6 min. A mouse was judged to be immobile when it floated in the water, in an
upright position, and made only small movements to keep its head above water. The
duration of immobility was recorded during the last 4 min of the 6-min test. A
decrease in the duration of immobility is indicative of an antidepressant-like effect.
Twelve to fifteen mice per group were tested.
2.9. Hole-board test
The hole-board test consisted of a 40 cm square plane with 16 flush mounted
cylindrical holes (3 cm diameter) distributed 4 4 in an equidistant, grid-like
manner. Mice were placed on the centre of the board one by one and allowed to
move about freely for a period of 10 min each. Two electric eyes, crossing the plane
from mid-point to mid-point of opposite sides, thus dividing the plane into four
equal quadrants, automatically signalled the movement of the animal (counts in
5min) on the surface of the plane (locomotor activity). Miniature photoelectric cells,
in each of the 16 holes, recorded (counts in 5 min) the exploration of the holes
(exploratory activity) by the mice. Twelve to fifteen mice per group were tested.
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The apparatus consisted of a base platform and a rotating rod with a diameter of
3 cmand a non-slippery surface. The rodwasplaced at a height of 15 cm from the base.
The rod, 30 cm in length, was divided into five equal sections by six disks. Thus, up to
five mice were tested simultaneously on the apparatus, with a rod-rotating speed of
16 r.p.m. The integrity of motor coordinationwas assessed on the basis of the number
of falls from the rod in 30 s according to Vaught et al. (1985). Those mice scoring less
than 3 andmore than 6 falls in the pretest were rejected (20%). The performance time
was measured before (pretest) and 15, 30 and 45 min after the beginning of the test.
Twelve to fifteen mice per group were tested.
2.11. Drugs
The following drugs were used: heparin sodium salt (mol. wt: approx. 6000),
clomipramine hydrochloride, amitriptyline hydrochloride, lithium chloride (Sigma,
Milan, Italy), xestospongin C, D-myo-inositol 1,4,5-trisphosphate hexasodium salt, L-
myo-inositol 1,4,5-trisphosphate hexapotassium salt (Calbiochem, Milan Italy).
Other chemicals were of the highest quality commercially available. Xestospongin C
was dissolved in 0.01% ethanol whereas all other drugs were dissolved in isotonic
(NaCl 0.9%) saline solution immediately before use. Drag concentrations were
prepared so that the necessary dose could be administered in a volume of 5 ml per
mouse by intracerebroventricular (i.c.v.) injection and 10 ml kg1 by subcutaneous
(s.c.) injection.
2.12. Drug administration
LiCl (0.4–400 mg kg1 s.c.) was administered 18 h before the forced swimming
test, heparin (0.08–6.6 nmol per mouse i.c.v.), xestospongin C (1–100 pmol per
mouse i.c.v.), D-myo-inositol (5 pmol per mouse i.c.v.) and L-myo-inositol (5 pmol per
mouse i.c.v.) were injected 15 min before behavioural test. Clomipramine
(25 mg kg1 s.c.) and amitriptyline (15 mg kg1 s.c.) were injected 30 min before the
test. D-amphetamine (2 mg permouse i.c.v.) was administered 15min before the hole
board test. Doses and administration schedule were chosen on the basis of time-
course and dose–response experiments previously performed in our laboratory
ODNs were i.c.v. injected once daily on days 1, 2 and 3. Behavioral tests were per-
formed on day 4, 24 h after the last i.c.v. injection of ODNs. To perform ODN time-
course experiments, the immobility time values were recorded on day 5 and 10
corresponding to 36 h and 7 days after the end of the ODN treatment, respectively. In
time-course, the hole board and rota rod tests’ ODNs were injected at doses of
0.5 nmol per mouse (anti-InsP3Rl and anti-InsP3R3), or 1 nmol per mouse (anti-
InsP3R2).
Brain areas to conduct western blotting and immunocytochemistry experiments
were collected on day 4, 24 h after the last i.c.v. injection of ODN at doses of 0.5 nmol
per mouse (anti-InsP3Rl and anti-InsP3R3), or 1 nmol per mouse (anti-InsP3R2), and
on day 11.
2.13. Statistical analysis
All experimental results are given as the mean þ S.E.M. An analysis of variance
ANOVA, followed by Fisher’s post hoc comparison, was used to verify significance
between two means of behavioural results. P values of less than 0.05 were consid-
ered significant.
3. Results
3.1. Antidepressant-like effect of pharmacological modulators of
InsP3R pathway
The administration of the InsP3 receptors antagonist heparin
(0.08–6.6 nmol per mouse i.c.v.) produced a dose-dependent
antidepressant-like effect (Fig. 1, panel A). The reduction of
immobility time produced by heparin (6.6 nmol per mouse i.c.v.)
was reversed by D-myo inositol (5 pmol per mouse i.c.v.) whereas it
remained unchanged by pre-treatmentwith L-myo-inositol (5 pmol
per mouse i.c.v.), used as negative control (Fig. 1, panel A). D-myo
inositol (5 pmol per mouse i.c.v.) and L-myo inositol (5 pmol per
mouse i.c.v.), when administered alone, did not modify the mouse
immobility time in comparison with control group (Fig. 1, panel A).
Similarly to heparin, xestospongin C (1–100 pmol per mouse
i.c.v.), antagonist of InsP3 receptors, showed antidepressant-like
properties (Fig. 1, panel B). LiCl, an inositol monophosphatase
inhibitor, produced an antidepressant-like effect in a dose-depen-
dent manner (0.4–400mg kg1 s.c.) (Fig.1, panel C). The decrease of
the immobility time produced by heparin, xestospongin C and LiClwas comparable to that exerted by clomipramine (25 mg kg1 s.c.)
used as reference drug (Fig. 1).
3.2. Cerebral InsP3Rl, InsP3R2 and InsP3R3 protein knockdown
induced by antisense treatment
The level of expression of InsP3Rl, InsP3R2 and InsP3R3 in the
cerebellum, cortex and hippocampus of knockdown animals was
detected in comparison with mice treated with dODN, used as
control ODN. Fig. 2 shows a representative immunoblot where
a prominent approximately 260 kDa protein band was observed in
the cortex (panel A) and the hippocampus (panel B), indicating
that all three receptor subtypes were expressed in the above-
mentioned cerebral areas. A statistically significant reduction of
the expression of InsP3Rl, InsP3R2 and InsP3R3 after aODN treat-
ment, in comparison with mice treated with the corresponding
dODN, was observed in terms of detected protein levels in the
cortex (Fig. 2a) as well as in the hippocampus (Fig. 2b). Densito-
metric analysis of all samples revealed that every aODN treatment
decreased expression of the corresponding receptors in both
cerebral areas investigated. A comparable inhibition of protein
expressionwas obtained in the cerebellum, area where InsP3Rs are
abundantly expressed and, for this reason, used as positive control
(data not shown). Levels of expression of InsP3Rl, InsP3R2 and
InsP3R3 proteins returned to normal 7 days after the end of the
aODN treatment (data not shown). Immunoprecipitation experi-
ments also produced similar results in both cortex and hippo-
campus (data not shown).
The dODN did not significantly change the level of immunos-
taining when compared with that of naive animals. Immunoblots
were re-probed for a protein considered to be not regulated as
b-actin and no significant density difference was revealed for this
protein between samples from the InsP3Rl, InsP3R2 and InsP3R3
down-regulated brain region (Fig. 2a and b). Cross-reactivity of the
primary antibodies used was excluded.
Brain slices of treated and control mice were immunostained to
show the localization and level of expression of InsP3Rs. Results
obtained in anti-InsP3Rl knockdown animals, taken as example,
were reported in Fig. 3. In the cerebellum of dODN-treated mice
InsP3Rl was highly expressed and concentrated in Purkinje cells
(Fig. 3a). A lower immunostaining was observed in anti-InsP3Rl
treated mice (Fig. 3b). This protein was also detected in the mouse
hippocampus (Fig. 3c) and, similarly to cerebellum, a reduction of
protein expression was observed in InsP3Rl knockdown animals
(Fig. 3d). RyR2 protein was used as positive control protein and no
difference in the protein expression was observed between control
and InsP3Rl knockdown mice (data not shown).
3.3. Antidepressant-like effect in InsP3Rl, InsP3R2 and InsP3R3
knockdown mice
The effect produced by a reduction of InsP3R protein levels was
evaluated in the mouse forced swimming test. Repeated adminis-
tration of anti-InsP3Rl induced an antidepressant-like effect in
a dose-dependent manner (0.1–5 nmol per mouse). A bell-shaped
curve was obtained (Fig. 4a). Similarly to anti-InsP3Rl, the admin-
istration of anti-InsP3R2 (Fig. 4b) and anti-InsP3R3 (Fig. 4c)
produced a dose-dependent antidepressant-like effect (0.1–3 nmol
per mouse i.c.v.). The i.c.v. administration of ODNs did not modify
the animal response in the forced swimming test. The immobility
time values recorded in the dODN-treated group were comparable
to those of the naive, saline-treated and vector-treated (DOTAP
13 mM) mice (Fig. 4d). In these experimental conditions the
administration of amitriptyline (15 mg kg1 s.c.) and clomipramine
(25 mg kg1 s.c.), used as reference compounds, produced a statis-
tically significant antidepressant-like effect (Fig. 4d). The decrease
80
100
120
140
160
180
200
220
i
m
m
o
b
i
l
i
t
y
 
t
i
m
e
 
(
s
)
∗∗
0.17 2.5
∗∗∗
3.3 6.6Heparin
∗∗
D-myo inositol
L-myo inositol
0.08 6.6 6.6
5.0
5.0
5.0
5.0
- - - - -
- - - - - - -
- -
- -
SAL CLO
A
B
80
100
120
140
160
180
200
220
i
m
m
o
b
i
l
i
t
y
 
t
i
m
e
 
(
s
)
LiCl CLO
∗∗
∗
∗∗
0.4 4 40 400
saline
08
100
120
140
160
180
200
220
i
m
m
o
b
i
l
i
t
y
 
t
i
m
e
 
(
s
)
CLO
∗∗
vehicle
1 10
∗∗
∗
30 50
xestospongin C
C
Fig. 1. Antidepressant-like effect of InsP3R pharmacological blockers. Antidepressant-like effect induced by heparin (panel A), xestospongin C (panel B) and LiCl (panel C) in the
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anti-InsP3R3 was of intensity comparable to that induced by the
antidepressant drugs amitriptyline and clomipramine (Fig. 4d).
To evaluate the reversibility of the aODN effects, mice were
treated with the aODNs on day 1, 2 and 3; 7 days after the last i.c.v.
injection, mice were killed and the cortex and hippocampus were
dissected and examined for the protein levels of InsP3Rl, InsP3R2
and InsP3R3 in comparison with mice treated with dODN. Fig. 5a
shows a representative immunoblot where three distinct prom-
inent protein bands of approximately 26 kDa, corresponding to
InsP3Rl, InsP3R2 and InsP3R3, were observed in the mouse
hippocampus. InsP3R subtypes protein expression in aODN treated
mice was similar to control animals. Time course experiments
showed that the antidepressant-like effect produced by the highest
effective doses of anti-InsP3Rl (0.5 nmol per mouse), anti-InsP3R2
(1 nmol per mouse) and anti-InsP3R3 (0.5 nmol per mouse), slowly
diminished 36 h after the end of repeated treatment and dis-
appeared after 7 days (Fig. 5b).
3.4. Effect of InsP3Rl, InsP3R2 and InsP3R3 knockdown on mouse
locomotor behaviour
Repeated administration of anti-InsP3Rl neither produced
behavioural side effect such as tremors, convulsions, etc. nor
induced lethality up to the dose of 5 nmol per mouse. By contrast,anti-InsP3R2 and anti-InsP3R3 at the dose of 5 nmol per mouse
produced convulsions and death in 90% and 80% of animals,
respectively. The dose of 3 nmol was endowed with a lower toxicity
(62.9–68.5% of lethality) and survived animals showed neither
tremorsnor convulsions. Treatmentwith lowerdoses didnot induce
any lethality. The aODNs were tested in order to unmask their
potential effect on mouse motor behaviour. The spontaneous
mobility (Fig. 6a) and the exploratory activity (Fig. 6b) of mice were
unmodified by pretreatment with aODNs in comparison with the
dODN group. D-amphetamine (2 mg kg1 s.c.), used as positive
control, significantly increased both parameters evaluated (Fig. 6a
and b). The lack of any impairment in the motor coordination of
animals pretreatedwith aODNs in comparisonwith the dODNgroup
was demonstrated (Fig. 6c). The highest effective doses of heparin
and xestospongin C did not modify mouse spontaneous mobility,
exploratory activity and motor coordination (data not shown).
4. Discussion
Our experiments show that InsP3R-mediated pathway involved
the modulation of depressive states in mice. Pharmacological
blockade of InsP3Rs activity as well as a gene-specific cerebral
InsP3Rl, InsP3R2 and InsP3R3 protein knockdown is endowed with
an antidepressant behaviour of intensity comparable to that
exhibited by clinically used antidepressant drugs.
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ical antagonists heparin (Jonas et al., 1997) and xestospongin C
(Gafni et al., 1997) were demonstrated by present results. I.c.v.
administration of both the membrane permeable low molecular
weight heparin (Jonas et al., 1997) and xestospongin C produced
a decrease of the immobility time in the mouse forced swimming
test. This effect was reversed by D-myo inositol, compound which
generates InsP3, whereas L-myo inositol, used as negative control,
did not produce any effect. These data demonstrate that the
heparin and xestospongin C antidepressant activity was related to
a blockade of cerebral InsP3Rs. An indication of a positive effect of
heparin in humans as well was reported. The complete disap-
pearance of depressive symptoms after addition of subcutaneous
calcium heparin to fluoxetine was observed in a patient suffering
from a recurrent depression resistant to conventional antidepres-
sant therapy (Maluquer et al., 2002). On the bases of our findings,
we can hypothesize that the beneficial effect of heparin might be
a consequence of its antidepressant activity.
To further elucidate the InsP3-mediated pathway in the induc-
tion of an antidepressant behaviour, LiCl, an uncompetitive inhib-
itor of inositol monophosphatase, which regenerates inositol frominositol monophosphate, was used. The LiCl-induced inhibition
depletes inositol and prevents the formation of InsP3 (Phiel and
Klein, 2001). LiCl pretreatment decreases the immobility time
indicating that the inhibition of the synthesis of InsP3 is necessary
to counteract the induction of a depressant condition. In support to
our findings, it has been reported that NCS-1, a high affinity, low
capacity, calcium binding protein, modulates calcium signalling by
enhancing InsP3-mediated activity of InsP3Rl. The association NCS-
l/InsP3Rl was attenuated by lithium (Schlecker et al., 2006).
Three different InsP3R isoforms are expressed in the central
nervous system. To further elucidate the involvement of
the InsP3R-mediated pathway in mood disorders, the role of types
1–3 InsP3Rs was investigated in a depressant task. InsP3Rl, InsP3R2
and InsP3R3 knockdown animals showed an antidepressant-like
behaviour indicating the importance of all three InsP3R isoforms in
the modulation of a depressive state. Present results further
elucidate the physiological role of supraspinal endoplasmic InsP3Rs
and give indication for the involvement of each InsP3R isoforms in
the pathological mechanism of mood disorders. In agreement with
present data, several studies have shown an overstimulated phos-
phoinositide signalling system in affective disorders. The majority
of clinical studies available have been conducted in peripheral
blood elements since the calcium mobilization studies require
fresh, viable cell preparations, which make postmortem samples
not always suitable. In particular, platelets of affected people are
often used as models for neurons because they have similar
signalling features and it is possible to obtain samples from affected
individuals. Results from depressed patients evidenced the exis-
tence of a greater sensitivity of inositol–phospholipid second
messenger system (Bohus et al., 1996) and an altered PIP2 hydro-
lysis (Mikuni et al., 1991; Karege et al., 1996; Pacheco et al., 1996;
Shimon et al., 1997; Pandey et al., 2001; Soares et al., 2001) in blood
cells and postmortem brains. Furthermore, elevated InsP3 binding
sites and expressed InsP3 receptor protein levels have been noted
in platelets from depressed patients (Dwivedi et al., 1998; Rosel
et al., 2000).
Among the three InsP3R isoforms, InsP3Rl appears to have
a prominent role. InsP3Rl knockdown animals showed a decrease
of immobility time of greater intensity than InsP3R2 and InsP3R3
knockdown mice. To obtain an immobility time decrease of
comparable intensity, a double anti-InsP3R2 and anti-InsP3R3
aODN concentration must be used. These data indicate that a lower
level of InsP3Rl protein expression inhibition is sufficient to obtain
a phenotype resistant to the induction of a depressive state. To
further support our results suggesting the importance of type 1
InsP3R in mood disorders, a reduction of InsP3Rl mRNA in rat brain
was observed after a single electroconvulsive shock (Kim et al.,
2001).
Type 1 InsP3R is themajor neuronal type of InsP3R in the central
nervous system, predominantly concentrated in cerebellar Purkinje
cells, cerebral cortex, CA1 region of hippocampus, basal ganglia and
thalamus (Mikoshiba, 1997; Ross et al., 1992). It is not surprising
that an altered InsP3Rl functionality at the central nervous system
level may be associated with pathological conditions. Loss of
InsP3Rl in mice is associated with ataxia and seizures (Matsumoto
et al., 1996), as well as a deficient cerebella long-term depression
(Matsumoto and Nagata, 1999). A several-fold reduction of immu-
nostained InsP3Rl was found in two cerebella obtained from
patients suffering from ataxia (Zecevic et al., 1999), indicating that
the above-mentioned findings on mice may apply to some forms of
ataxia in humans as well. In several neurodegenerative diseases,
such as Alzheimer disease and Huntington disease, and in brain
ischemia, InsP3Rl appears to be selectively down-regulated (Zhang
et al., 1995; Tang et al., 2003; Haug et al., 1996; Kasri et al., 2004).
We now postulate the possible involvement of the InsP3Rl subtype
in depressive disorders.
Fig. 3. Distribution and levels of InsP3Rl protein in InsP3Rl knockdown animals. Reduction of InsP3Rl protein expression in the mouse brain of InsP3Rl knockdown mice.
Representative photomicrographs for InsP3Rl immunoreactivity in cerebellar Purkinje cells body (P) (panels A and B) and hippocampal slices (panels C and D).
N. Galeotti et al. / Neuropharmacology 55 (2008) 1156–1164 1161An antidepressant-like behaviour was also observed in InsP3R2
and InsP3R3 knockdown mice. Although the type 2 InsP3R is
present in many tissues, high levels are found in spinal cord and
glial cells (Sharp et al., 1999). At the subcellular level, it was found in
the cell body but was excluded from the nuclear region (Sheppard
et al., 1997; Simpson et al., 1997). Type 3 InsP3R is found in the
kidney, gastrointestinal tract, pancreatic islets (Taylor et al., 1999;
Patel et al., 1999; Nathanson et al., 1994). Loss of InsP3R3 is found in
humans with bile duct obstruction (Shibao et al., 2003). Exocrine
dysfunction of the salivary glands and pancreas was observed in
InsP3R2 and InsP3R3 double knock-out mice (Futatsugi et al.,
2005). These results indicate the importance of InsP3R3 at
peripheral level. However, it is also detected in some neurons,80
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role of these two receptor subtypes in the central nervous system is
not clearly elucidated. Present results provide the first evidence for
an involvement of types 2 and 3 InsP3R in the mechanism under-
lying the induction of a depressive condition.
The specific gene expression knockdown of each of the three
InsP3R subtypes was obtained by an oligonucleotide antisense
strategy. To investigate the role played by InsP3Rs at the central
nervous system level, the aODNs against the types 1–3 InsP3R were
administered directly into the mouse cerebral ventricles in order to
avoid the appearance of peripheral effects. aODNs are short
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therefore, transiently inactivating single genes and down-regu-
lating the synthesis of the encoded protein. Immunoblotting,
immunoprecipitation and immunocytochemistry experiments
illustrated a selective decrease of InsP3Rl, InsP3R2 and InsP3R3
protein levels in the cerebellum, hippocampus, and cortex of
animals treated with the corresponding aODN in comparison with
the degenerated oligonucleotide (dODN)-treated mice. These
results showed that the antidepressant phenotypic effect was
related to a selective knockdown of the InsP3R isoforms. Further-
more, the dODN, used as control for the unspecific effects attrib-
utable to the administration of nucleic acids irrespective of their
specific sequence, did not modify the immobility time in compar-
ison with naive or saline- and vector-i.c.v. injected mice. This
observation ruled out the possibility that the antidepressant
behaviour showed by InsP3R knockdown animals may have
resulted from a sequence-independent action on cerebral struc-
tures. The immunoblotting results are in agreement with recent
data obtained in our laboratory which demonstrated a widespread
cerebral reduction of InsP3R subtypes in knockdownmice (Galeotti
et al., 2007). Present results showed that a cortical and hippo-
campal selective reduction of InsP3R isoforms can be obtained with
a aODN concentration at least three times lower than that previ-
ously used by us.
The antidepressant-like effect induced by anti-InsP3Rl, anti-
InsP3R2 and anti-InsP3R3 decreased 36 h after the end of the aODN
treatment and disappeared after 7 days. The reversibility of the
induced phenotype is a requirement for a proper and correct
functionality of aODNs. It indicates a lack of irreversible damage or
toxicity on cerebral structures as well.
aODN-treatment produced a bell-shaped curve of modulation of
the immobility time. This biphasic effect was similar to the effectproduced by the physiological modulators of InsP3Rs (Iino, 1990;
Finch et al., 1991).
The forced swimming test is widely used to predict the anti-
depressant action of drugs in humans. In this test, the majority of
antidepressants decreased the immobility time of mice and their
effectiveness correlates significantly with clinical potency (Petit-
Demouliere et al., 2005). However, this animal model has also some
drawbacks represented by the possibility to obtain some false
positives or negatives by drugs that modify motor activity, which,
therefore, may alter the immobility time values recorded. aODN
behavioural effects were tested before the forced swimming test
was performed, to make sure that treatments did not alter the
normal locomotor activity of the mice. An influence of the
substances used on spontaneous motility has been excluded by
using the hole-board test. Not only a modified spontaneous
mobility but also altered motor coordination could lead to
a misinterpretation of the results obtained. A rota rod test was,
therefore, performed and any alteration of the motor activity
induced by aODN administration at the highest effective doses was
excluded. The results of the rota rod and hole-board tests were of
particular relevance since it has been observed that mice lacking
N. Galeotti et al. / Neuropharmacology 55 (2008) 1156–1164 1163type 1 InsP3R showed severe ataxia (Matsumoto et al., 1996) and
motor discoordination (Ogura et al., 2001). This discrepancy can be
explained by taking into account that, conversely to the knockout
strategy, the antisense strategy permits to modulate the degree of
inhibition of the target protein expression. A phenotypic effect
devoid of severe toxicity can be obtained. Moreover, compensatory
effects taking place during mice development, which can mask
important phenotypic effects, are avoided. It should also be noted
that higher doses of anti-InsP3R could not be investigated since
they induced signs of toxicity (tremors, convulsions etc.) and/or
death in animals. The induction of toxicity can also be considered as
an indication not only of the diffusion of these compounds in the
brain, but also of the consequent reaching of key targets.
Seen as a whole, present results indicate the involvement of the
InsP3R-mediated pathway in the modulation of depressive states.
In particular, cerebral reduction of types 1–3 InsP3R expression
induces an antidepressant-like effect in mice, identifying cerebral
InsP3R isoforms as critical targets in the pathological mechanism of
depressive disorders. Modulation of InsP3R activity might be useful
for the development of new therapeutical strategies for the treat-
ment of mood disorders.
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